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Objectives: Medicine shortages are a global phenomenon. A growing number of 
reports indicate the problem is increasingly affecting the European pharmaceutical 
market. The present study aims to investigate the characteristics, determinants, 
legal aspects and management of medicine shortages in Belgium, France and from 
the perspective of the European Union. MethOds: A review of scientific and grey 
literature was performed. The legal framework on European and national level 
was reviewed. Primary qualitative data was collected through 22 semi-structured 
interviews with key representatives of health care systems’ stakeholders on the 
national and European level. Results: France reported three times more shortages 
than Belgium. However, the main therapy area, the major cause and the dynamics 
of medicine shortages were analogous between the two countries. Determinants 
of medicine shortages were categorised in manufacturing problems, distribution 
and supply issues, and economic-related challenges. Manufacturing problems 
were most frequently reported as the primary cause of medicine shortages. Laws 
and regulations related to medicine shortages are more extensive in France than 
Belgium. Several preventive and responsive measures were identified to address 
such shortages. cOnclusiOns: Although medicine shortages are country-specific, 
the underlying mechanisms of medicine shortages appear to be similar in Belgium 
and France. Economic aspects seem to play a central role in the phenomenon of 
medicine shortages, as it influences stakeholders’ business decisions. The impact 
of the legal framework around medicines on the occurrence of medicine shortages 
may be limited. Collaboration, communication and coordination are key to any 
effective approach to address medicine shortages.
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Objectives: Firstly, to review whether medicines that have received expedited 
regulatory approval in the European Union (EU) subsequently received positive 
recommendations from selected Health Technology Assessment (HTA) agen-
cies in the EU. A second objective was to understand the reasons for negative 
appraisals of these medicines by EU HTA agencies. MethOds: Medicines that 
have received Conditional Marketing Authorisation (CMA) by the European 
Medicines Agency (EMA) were identified from the EMA website. Websites of HTA 
agencies in the United Kingdom (NICE, SMC); Ireland (NCPE), France (HAS) and 
Germany (IQWiG) were searched to ascertain whether these medicines had been 
appraised. Appraisal reports were reviewed. For medicines with at least one nega-
tive appraisal, reason (s) for the negative appraisal were identified. Results: 
13 medicines have received CMA in the EU. 10 of these medicines have received 
a negative appraisal by at least one HTA agency (either ‘not recommended’ or 
deemed to offer ‘no additional benefit’ over existing treatment). Of the 10 medi-
cines with at least one negative appraisal, 8 are oncology medicines. The most 
common reason for a negative appraisal (relevant to 9 of the 10 medicines) was 
insufficient or uncertain clinical effectiveness. Uncertain cost-effectiveness in 
relation to the proposed treatment cost was mentioned as a source of uncertainty 
for 5 of the 10 medicines. cOnclusiOns: Despite receiving expedited regulatory 
approval, patient access to innovative medicines in the EU may be delayed due 
to negative appraisal of these medicines by HTA agencies (most often due to a 
relative lack of data on clinical effectiveness). Such delays obviate the intention 
of expedited regulatory review of medicines.
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Objectives: To provide a comprehensive description of the current Drug 
Reimbursement Systems in Algeria and to compare it to two archetypes drug reim-
bursement systems in France and UK and to a system in a middle income country: 
Turkey where the HTA has been recently implemented. MethOds: We collected and 
reviewed relevant information to describe the health care and drug reimbursement 
systems in these countries; we reviewed the legal framework and procedure docu-
ments. For Algeria, in addition to the data and information collected, we conducted 
informal interviews supplemented by a survey among key stakeholders. Results: 
Compared to the UK, no similarities were found. This is probably due to the cultural 
differences and the lack of expertise in the use of cost-effectiveness approaches. 
Compared to the France, we didn’t find similarities, except the final decision which 
is taken at the Ministry level. This is due to the administrative nature and the lack 
of transparency of the assessment in Algeria especially where the methods as well 
as the results of the assessment are not explicitly expressed. Compared to Turkey, 
we found some similarities in terms of process, but not in terms of methods as this 
country is now more familiar with the HTA approach. cOnclusiOns: Our study 
shows that the implementation of HTA differs according to cultural and financial 
factors and to expertise capacity in data collection, analysis and use in the decision 
making process. The use of HTA in the drug evaluation and reimbursement system 
in Algeria is underestimated and underdeveloped. That’s why before adopting HTA 
approaches in the pharmaceutical sector, the Algerian authorities should consider 
these factors and improve the data quality and decision process transparency. This 
is becoming vital as cost of drugs is increasing and the fiscal space will be more 
constrained in the near future.
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the reduction of pharmaceutical expenditure was one of the main targets for fiscal 
adjustment. The purpose of this study was to assess the usage of generic medicines 
in Greece, as a key driver for savings from the pharmaceutical market, and compare 
it with that of other major European countries. MethOds: IMS data from several 
European countries was collected in terms of the overall retail pharmaceutical mar-
ket and the consumption of generic medicines in each of them. Focus was placed 
on the top-10 genericized molecules for Greece including alendronic acid, atorv-
astatin, carvedilol, clarithromycin, clopidogrel, donepezil, fluconazole, olanzapine, 
omeprazole and simvastatin. To ensure an “apples-to-apples” comparison across 
countries, the study focused on the retail market only (excluding hospitals) given 
that, in Greece, there is no publicly-available data for pharmaceutical consump-
tion within the hospital setting. Results: The analysis indicated that, in Greece, 
the penetration of generic medicines within the top-10 genericized molecules was 
65% in terms of volume, with off-patent medicines holding the remaining 35%. 
According to IMS data, Greece had a lower penetration of 21 percentage points 
(-24%) versus the weighted European average and -8.2 percentage points (-11%) 
versus the cluster of Southern European countries plus Ireland for calendar year 
2013. cOnclusiOns: Generic penetration within the 10 largest genericized mol-
ecules, in Greek retail-pharmacy setting, is significantly lower versus the weighted 
average of major European countries but also compared to that of countries in 
similar economic situation with Greece.
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Objectives: The practice of generic medicines prescribing, dispensing and 
substitution in developing countries has been controversial among health care 
professionals, particularly due to issues on quality, safety and efficacy. These con-
troversies are as a result of inter-country differences in policies and laws as well 
as individualized knowledge and attitudes of pharmacists pertaining to generic 
medicines. This study primarily aims to assess the knowledge, attitudes, and prac-
tices of community pharmacists in Qatar towards generic medicines. MethOds: A 
cross-sectional study using a pretested paper-based survey was conducted among 
a random sample of community pharmacists in Qatar. The data were analyzed 
using IBM–SPSS® version 20. Both descriptive and inferential statistical analyses 
were applied. Results: A total of 160 surveys were distributed to community phar-
macists of which 118 were returned (response rate, 74%). The mean total score of 
generic medicines knowledge among the pharmacists was 6.8 ± 1.6 (maximum 
possible score was 10). Years of practice as well as place of obtaining academic 
degree did not influence knowledge score. Approximately 72% of the pharmacists 
supported generic substitution for brand name drugs in all cases where a generic 
medicine is available and the majority (93%) agreed that pharmacists should be 
given generic substitution right. Nearly 61% of the pharmacists considered lack 
of proven bioequivalence to original brands as an important barrier for selecting 
generic medicines and 55% rated “lack of policy for directing the practice of generic 
medicine” as an important barrier. cOnclusiOns: In order to enhance the quality 
use of and to promote the practice of generic medicines in Qatar, an educational 
program should be implemented. A national generic medicine policy and guidelines 
are warranted in the State of Qatar.
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Objectives: Encouraging generic drug use has reduced health care costs for payers 
and consumers, but the rate of branded medications therapeutically interchange-
able to generic is not equal across medications disease states. The extent to which 
different systems of care are able to substitute towards generics is not well under-
stood. This study defined and measured the maximum generic rate (MGR) of cur-
rently prescribed drugs and illustrated differences across drugs associated with 
selected underlying diseases. MethOds: Using information in prescription claims 
data, drugs were classified into “potentially generic substitutable” or not based on 
clinical consensus regarding the following algorithm: 1. They did not having have 
a narrow therapeutic index (NTI) as defined by the Food and Drug Administration 
(FDA); 2. Did not belong to one of six protected classes of drugs in Medicare D; 3. They 
were substitutable with a generic medication of the same chemical entity; 4. They 
were therapeutically interchangeable with a generic in the same class which was 
thought clinically to have class effect benefits and minimal risk of harm in switch-
ing. A maximum generic rate (MGR) was defined as the percent of prescriptions 
that could be generic. This rate was examined overall and across drugs known to 
be associated with illustrative diseases including hypertension, diabetes mellitus, 
and obstructive lung disease. Results: The MGR ranged from 100% for drugs used 
in hypertension to 26.7% for drugs used in obstructive lung disease. The overall 
maximum possible generic rate (MGR) was 83.6%. cOnclusiOns: Payers wishing 
to promote generic substitution should incorporate the potential for substitution 
toward clinically appropriate generic medications as part of incentives for generic 
utilization to avoid unintended consequences of using a fixed target rate. A practical 
methodology for determining a MGR is offered here.
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Objectives: In European hospitals, budgetary pressure is driving centralized 
purchasing and increasing the importance of procurement in market access. 
Centralized purchasing is thought to lead to cost savings through stronger nego-
tiating power, economies of scale and reduced inventory. The objective of this 
study was to understand the procurement methods for disposable medical devices 
employed by European hospitals and their impact on market access. MethOds: 
A review of hospital purchasing practices was conducted in France, Germany and 
England, including published articles and government websites. Twelve 45-60 min-
ute telephone interviews were conducted with hospital decision makers (pur-
chasers, pharmacists and clinicians) in 2013. Results: Most disposable medical 
devices are evaluated at the facility level by committees made up of clinicians, 
procurement specialists, pharmacists and management. France and Germany 
require listing on the facility formulary and typically procure via tendering and 
group purchasing. England has a national procurement body but hospitals regu-
larly purchase products directly from the manufacturer. All three countries report 
that austerity measures are causing many facilities to limit the number of products 
per category. Product trials and clinician preference are seen as the main drivers 
of adoption however clinicians are under increasing pressure to justify costs. 
Hospital purchase decisions are increasingly likely to be based on non-product 
specific attributes such as total cost of purchasing including volume discounts, 
broad portfolio of products, and administrative costs. cOnclusiOns: In the cur-
rent environment, market access for disposable medical devices will require a 
strong economic argument in addition to evidence of superior quality. Although 
clinicians still drive the adoption of consumable medical devices, in the absence 
of a strong clinician preference, non-product specific attributes may determine 
market access. Manufacturers can support their economic messaging along cat-
egories of inventory reduction and a broad portfolio of products that allows for 
administrative efficiencies and reduced shipping costs.
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Objectives: The Portuguese National Health System (NHS) identified the 
need to easily access information that allowed identification of all medical 
devices (MDs) with their respective manufacturers, distributors, characteristics, 
and purposes. The objective of the creation of an information system is to col-
lect, store and analyze data of each MD and to provide NHS resources manage-
ment, health technology assessment (HTA), as well as data about the Portuguese 
market. MethOds: A system consisting of a database that is a repository, and 
an application system that stores the information was built. For the registry of 
information all MDs should disclose their respective instructions of use, labels 
and price. The concept of unique medical device and a process to assign a code to 
each device was designed, and tested by collecting data from NHS acquisitions. 
The prescription of medical devices is made by code, with all information online. 
A model for communication between the health regulatory agency and market 
operators was also devised, as well as rules and codes of procedure. Results: The 
creation of this system in 2011 allowed for the coding of 20% of all registered MDs 
(n= 838000) up to June 2014. This has allowed for the elimination or withdrawal of 
16% (n= 136000) of references, thus keeping the registries up to date. The coding 
permitted the comparison of devices and the management of total expenditure in 
MDs by hospitals of the NHS. cOnclusiOns: The system provides solid informa-
tion about available MDs in the market, their respective manufacturer, distributor 
and pricing to which they are sold to the NHS. The system is a support for decision 
makers, payers, and HTA processes. It facilitates the management and traceability 
of medical devices in hospitals and has impact on reimbursement, access and 
pricing varies by market.
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Objectives: Rapid increase of costs of reimbursement in Poland led to redesign of 
the drug pricing mechanisms. As a result a new law which brought revolutionary 
changes to the health care system was introduced in 2012. The aim of this work is 
to summarize the two years of new drug policy in Poland and to present mecha-
nisms that resulted in substantial savings in reimbursement costs. MethOds: 
Few savings-generating mechanisms were implemented in the new reimburse-
ment law: negotiations of prices, new method of calculation of reimbursement 
limit (resulting in higher co-payment) and also formal obstacles in obtaining pre-
scriptions for reimbursed products (some reimbursed drugs, i. e. antibiotics, due 
to formal issues are prescribed with 100% co-payment). The first and the third 
reason result in lower overall costs of reimbursed medicines, while the second 
reason influences the proportion of costs borne by the National Health Fund. We 
have analyzed data on prices of reimbursed drugs before 2012 and after imple-
mentation of the new law (currently the prices may change every two months). 
We have then compared the amount of sales of those drugs, costs of reimburse-
ment and patients’ co-payment. For some reference groups (i. e. oral aromatase 
inhibitors) we made in-depth analysis of pricing mechanisms. Results: In 2012 
total public expenditures amounted to 2.3 billion EUR, 83% of the planned budget, 
which gave 460 million EUR savings as compared to 2011. In 2013 the drug budget 
was executed in 87%, resulting in 430 million EUR savings. Saving were driven by 
price negotiations, but also by mechanisms of lowering the reimbursement limit, 
i. e. in case of oral aromatase inhibitors the reimbursement limit was lowered by 
half during 2012-2013. cOnclusiOns: The new reimbursement law resulted in 
substantial savings in costs of drugs. The success is however relative, as costs of 
drugs were partially shifted towards patients.
Objectives: The Moroccan government announced new public and hospital 
prices for 5308 drugs in April 2014. These price cuts came into force in June 2014. 
The study examines the price changes and analyzed the potential impact of the 
price cuts on pharmaceutical companies operating in the market. MethOds: 
Standard statistical methods were used to analyze government provided data in 
order to identify general trends within the pricing notification. Secondary sources 
were then examined to determine the general pricing rationale. Results: The 
price notification included 5308 drugs (note duplication occurs where a brand 
name has multiple formulations). Examining public prices: 390 of the drugs were 
newly listed on the list for public purchase, a further 2968 saw no price increase 
and two drugs saw modest price increases. Public price declines were seen for 
1948 drugs with the level of decline covering a range of 1635 percentages between 
0.006% and 78.6%. Average public price, excluding drugs with no decline, saw an 
average decline of 13.6% and median decline of 6.5%. All the 5308 drugs already 
had an existing hospital price, however 114 of these drugs saw no pricing change. 
Of the 5194 drugs which did see a price decline this varied across a range of 
2559 different percentages between 0.001% and 79.8%. The average hospital price 
decline, excluding drugs which saw no decline, was 9.3% and the median was 
5.8%. cOnclusiOns: The large range of pricing declines suggests that the prices 
were not indicative of a formulaic event such as currency fluctuation changes. 
This also means that there is a differential impact on pharma companies, with 
certain parts of their portfolio being more protected than others.
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Objectives: Unequal access due to delays or non-availability of medicines denies 
patients treatments they need and contributes to inequality across Europe. The 
EFPIA previously monitored access delays via the “Patients Waiting to Access 
Innovative Therapies (WAIT)” indicator, however; this has not been updated 
since 2011. Following the 2012 EC Transparency Directive 89/105/EEC mandating 
no more than 120 days of delay for national pricing and reimbursement deci-
sions, an updated evaluation is needed. MethOds: IMS MIDAS data was used to 
identify the first sale for all EMA-approved non-generic, non-biosimilar products 
since 2008 in 15 EU markets. The delay (from approval to first sale) was noted for 
each product and market and compared to the EFPIA Patients WAIT indicator for 
2008-2010. Annual average delays were calculated over the 2008-2013 period and 
for available products, an analysis of minimum and maximum delay performed 
for each market. Additional analyses were performed for trends within and across 
markets, and to identify progress and variations. Results: Improvements across 
the 2008-2012 period give cause for optimism in most European markets, as delays 
have fallen sharply in almost all markets, from an average of 524 days in 2008 to 
281 days in 2012, with only Greece showing no real improvement. However; abso-
lute availability of new medicines has varied greatly by market, with same-year 
availability of EMA-approved medicines declining to just 41% on average in 2013. 
Notable declines were seen in Greece, Spain, Romania and Portugal, suggesting 
that economic difficulties may lead some governments to refuse reimbursement, 
rather than simply delay decisions. cOnclusiOns: This updated access analysis 
shows that while delays are shortening, absolute access for patients is not always 
improving. Some new access rules such as “class C” drugs in Italy (access without 
funding), may send misleading signals, and underscore the need for monitoring 
of true access across Europe.
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Objectives: Market Access (MA) is key for medical devices given recent changes in 
regulation from one side, and pressures on costs from the other side. Nevertheless, 
there is scant evidence on how MA works in the medical device industry and 
whether it works effectively. The aims of the present study are to illustrate current 
gaps in MA for medical devices and to recommend future actions to make this 
function more effective. MethOds: We conducted a literature review aimed at 
gathering a clear picture of current state of the art on MA for medical devices and 
at highlighting major gaps vis-à-vis other industries (e.g. pharmaceuticals). Based 
upon the review’s findings, we carried out an e-survey to small, medium, and large 
device companies operating in the EU in order to understand: i) how MA is perceived 
and actually organised, ii) which are the main perceived obstacles to MA, iii) how 
companies invest in market access and at which stage of medical device develop-
ment, and iv) what the main challenges are to a more efficient market access pro-
cess. Results: The findings of the literature review and preliminary results of the 
e-survey are presented. cOnclusiOns: MA is an under-developed function in the 
medical device industry and in certain cases its role is not fully exploited. Although 
the pharmaceutical industry doesn’t represent a fully appropriate benchmark, MA 
for medical devices is even less developed when compared to its full potential. A 
different approach is needed to deal with new changes in the regulation and policy 
arenas aimed at synergistically encompassing knowledge, expertise and operating 
tools from public affairs, medical departments, pricing & reimbursement, health 
economics and marketing.
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